Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
7 min read
Artios Pharma Limited Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Artios Pharma Limited 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Arsenal Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Arsenal Biosciences, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
6 min read
Ascelia Pharma AB (publ) Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Ascelia Pharma AB (publ) 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Arthex Biotech S.L. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Arthex Biotech S.L. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Arena Pharmaceuticals, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Arena Pharmaceuticals, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
argenx SE (ENXTBR:ARGX) Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
argenx SE (ENXTBR:ARGX) 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Ark Biosciences Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Ark Biosciences Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Arrowhead Pharmaceuticals, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Arrowhead Pharmaceuticals, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
6 min read
Arrogene, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Arrogene, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Arcturus Therapeutics Holdings Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Arcturus Therapeutics Holdings Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Arcutis Biotherapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Arcutis Biotherapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Arcus Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
3 August 2026
Arcus Biosciences, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
<
1
<<
1114
1115
1116
1117
1118
>>
2260
>